Alcohol Consumption and Autoimmune Diseases
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(2), С. 845 - 845
Опубликована: Янв. 20, 2025
Alcohol
is
the
second-most
misused
substance
after
tobacco.
It
has
been
identified
as
a
causal
factor
in
more
than
200
diseases
and
5.3%
of
all
deaths
associated
with
significant
behavioral,
social,
economic
difficulties.
As
alcohol
consumption
may
modulate
immune
system’s
regulatory
mechanisms
to
avoid
attacking
body’s
tissues,
it
proven
play
dichotomic
role
autoimmune
(ADs)
based
on
quantity
consumption.
In
this
review,
we
report
updated
evidence
ADs,
focus
addiction
human
biological
system
relationship
between
them,
risk
or
protective
factor.
Then,
narrative
main
most
studied
ADs
where
represents
key
modulator,
including
thyroiditis,
multiple
sclerosis,
rheumatoid
arthritis,
systemic
lupus
erythematosus,
diabetes,
allergic
rhinitis,
primary
biliary
cholangitis.
at
low–moderate
dosages
seems
mostly
have
these
diseases,
while
higher
dosages,
collateral
risks
surpass
possible
benefits.
The
specific
by
which
low-to-moderate
intake
relieves
AD
symptoms
are
not
yet
fully
understood;
however,
emerging
studies
suggest
that
immunomodulatory
effect,
potentially
altering
balance
anti-inflammatory
innate
adaptive
cells,
well
cytokines
(via
NF-κB
NLRP3
pathways).
might
influence
composition
gut
microbiome
(increasing
amounts
beneficial
microbes)
production
their
fatty
acid
metabolites,
such
short-chain
acids
(SCFAs)
polyunsaturated
(PUFAs),
elevated
concentrations
acetate,
high-density
lipoprotein
(HDL),
nitric
oxide
(NO).
Unfortunately,
definite
acceptable
daily
(ADI)
ethanol
complicated
establish
because
many
despite
interesting
content
findings,
there
limit
applicability
should
be
weighed
cases
alcoholic
drinking
recommendations.
aim
future
those
pathways
involved
alcohol-protective
various
strategies
intake.
Язык: Английский
Comparative activity of dimethyl fumarate derivative IDMF in three models relevant to multiple sclerosis and psoriasis
FEBS Open Bio,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 17, 2025
Dimethyl
fumarate
(DMF)
is
an
anti‐inflammatory
and
immunoregulatory
medication
used
to
treat
multiple
sclerosis
(MS)
psoriasis.
Its
skin
sensitization
property
precludes
its
topical
use,
which
unfortunate
for
the
treatment
of
Isosorbide
di‐(methyl
fumarate)
(IDMF),
a
novel
derivative
DMF,
was
synthesized
circumvent
this
adverse
reaction
unlock
potential
delivery,
could
be
useful
treating
psoriasis
in
subpopulation
psoriatic
MS
patients,
as
well
general
population.
Here,
we
compared
therapeutic
non‐sensitizing
with
DMF
version
Diroximel
three
skin‐
neuroinflammation
models:
lck‐GFP
zebrafish,
activated
BV‐2
murine
microglia
human
T‐lymphocyte
Jurkat
cell
line.
The
results
provide
comparative
evaluation
bioactivity
these
related
chemical
entities
models
relevant
expose
several
advantages
unique
IDMF.
Язык: Английский
The role of Neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in MS and AQP4-NMOSD: Advancing clinical applications.
eNeurologicalSci,
Год журнала:
2025,
Номер
38, С. 100550 - 100550
Опубликована: Янв. 6, 2025
Fluid
biomarkers
such
as
Glial
Fibrillary
Acidic
Protein
(GFAP)
and
Neurofilament
Light
(NfL)
play
important
roles
in
the
diagnosis,
monitoring,
evaluation
of
therapeutic
responses
conditions
Multiple
Sclerosis
(MS)
Aquaporin-4
Neuromyelitis
Optica
Spectrum
Disorder
(AQP4-NMOSD).
These
offer
key
insights
into
underlying
pathophysiological
mechanisms
these
diseases,
enabling
effective
follow-up
personalized
treatment
approaches,
which
are
essential
for
improving
patient
outcomes.
Herein,
we
synthesize
structural
attributes,
functional
roles,
clinical
significance
GFAP
NfL
context
MS
AQP4-NMOSD.
We
explore
critical
implications
disease
manifestation
progression,
emphasizing
necessity
to
develop
standardized
methodologies
multicentric
studies
confirm
their
applicability.
Язык: Английский
Dilemmas in the differential diagnosis of pediatric multiple sclerosis
Medicinska istrazivanja,
Год журнала:
2025,
Номер
58(1), С. 75 - 81
Опубликована: Янв. 1, 2025
Multiple
sclerosis
(MS)
is
a
chronic,
inflammatory,
and
neurodegenerative
disease
of
the
central
nervous
system
(CNS).
It
typically
presents
in
early
or
middle
adulthood,
pediatric-onset
MS
(POMS),
defined
by
first
attack
occurring
before
age
18,
less
common.
Current
data
from
Danish
Sclerosis
Registry
indicates
that
nearly
3%
patients
had
onset
18.
In
comparison
with
adult-onset
MS,
POMS
have
more
inflammatory-active
course,
resulting
frequent
relapses,
but
slower
long-term
disability
accumulation.
POMS,
diagnostic
dilemmas
may
include
differentiating
acute
disseminated
encephalomyelitis
(ADEM)
myelin
oligodendrocyte
glycoprotein
antibody-associated
(MOGAD),
both
which
most
commonly
occur
among
children
share
some
clinical
imaging
features
MS.
Inherited
leukodystrophies
should
be
considered
differential
diagnosis
only
select
cases,
as
their
hallmark
feature-a
progressive
course-distinguishes
them
non-progressive
acquired
demyelinating
syndromes,
including
neuromyelitis
optica
spectrum
disorder.
It's
important
to
remember
magnetic
resonance
(MRI)
brain
spinal
cord
essential
for
establishing
timely
accurate
POMS.
MRI
helps
exclude
alternative
diagnoses,
allowing
prompt
initiation
effective
treatment.
Язык: Английский
Microglia-astrocyte crosstalk is regulated by Astragalus polysaccharides mediated through suppression of Sema4D-PlexinB2 signaling in experimental autoimmune encephalomyelitis
Brain Research,
Год журнала:
2024,
Номер
1845, С. 149275 - 149275
Опубликована: Окт. 12, 2024
Язык: Английский
New views on the complex interplay between degeneration and autoimmunity in multiple sclerosis
Frontiers in Cellular Neuroscience,
Год журнала:
2024,
Номер
18
Опубликована: Авг. 5, 2024
Multiple
sclerosis
(MS)
is
a
frequently
disabling
neurological
disorder
characterized
by
symptoms,
clinical
signs
and
imaging
abnormalities
that
typically
fluctuate
over
time,
affecting
any
level
of
the
CNS.
Prominent
lymphocytic
inflammation,
many
genetic
susceptibility
variants
involving
immune
pathways,
as
well
potent
responses
neuroinflammatory
component
to
immunomodulating
drugs,
have
led
natural
conclusion
this
disease
driven
primary
autoimmune
process.
In
Hypothesis
Theory
article,
we
discuss
emerging
data
cast
doubt
on
assumption.
After
three
decades
therapeutic
experience,
what
has
become
clear
modulators
are
highly
effective
at
suppressing
inflammatory
relapses,
yet
exhibit
very
limited
effects
later
progressive
phase
MS.
Moreover,
neuropathological
examination
MS
tissue
indicates
degeneration,
CNS
atrophy,
myelin
loss
most
prominent
in
stage,
when
inflammation
paradoxically
wanes.
Finally,
observations
such
"progression
independent
relapse
activity"
"silent
progression,"
now
thought
take
hold
early
course,
together
argue
an
underlying
"cytodegenerative"
process,
likely
targeting
myelinating
unit,
may
fact
represent
proximal
step
complex
pathophysiological
cascade
exacerbated
overlay.
Parallels
drawn
with
more
traditional
neurodegenerative
disorders,
where
proteopathy
prion-like
propagation
toxic
misfolded
species
known
play
key
role.
A
potentially
pivotal
contribution
Epstein-Barr
virus
B
cells
process
also
discussed.
Язык: Английский
Eficácia da terapia anticorpo monoclonal em crianças com encefalite autoimune: uma nova perspectiva no tratamento neurológico pediátrico
Anderson Gustavo Santos de Oliveira,
Jaciara Maria Parede Costa,
Iara Sabrina Parede Costa
и другие.
Cuadernos de Educación y Desarrollo,
Год журнала:
2024,
Номер
16(12 Edição Especial), С. e6944 - e6944
Опубликована: Дек. 16, 2024
A
encefalite
autoimune
(EA)
é
uma
doença
neurológica
rara
que
afeta
crianças,
caracterizada
pela
inflamação
do
cérebro
por
resposta
imunológica
inadequada,
frequentemente
associada
à
produção
de
autoanticorpos.
Os
pacientes
pediátricos
podem
apresentar
vários
sintomas,
incluindo
convulsões,
distúrbios
psiquiátricos
e
alterações
cognitivas
graves.